A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia

Drug Category: Array
Conference Category: Array
Lead Author: Sharman J, et al.
Published Date: 22/02/2021
Download Link: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30433-6/fulltext
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top